Craig Parker
Chief Executive Officer at SURROZEN, INC.
Net worth: 12 691 $ as of 30/04/2024
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| David Woodhouse | M | 54 |
Surrozen Operating, Inc.
 Surrozen Operating, Inc. BiotechnologyHealth Technology Surrozen Operating, Inc. operates as a biopharmaceutical company that focuses on harnessing the Wnt pathway for applications in regenerative medicine. The firm implements a surrogate Wnt platform with the potential to unlock stem cell control in an array of human tissues. The company was founded by K. Christopher Garcia, Roeland Nusse, Calvin J. Kuo, Hans Claudia and Claudia Janda in 2015 and is headquartered in South San Francisco, CA. | 4 years |
| Mace Rothenberg | M | 67 |
Surrozen Operating, Inc.
Surrozen Operating, Inc. BiotechnologyHealth Technology Surrozen Operating, Inc. operates as a biopharmaceutical company that focuses on harnessing the Wnt pathway for applications in regenerative medicine. The firm implements a surrogate Wnt platform with the potential to unlock stem cell control in an array of human tissues. The company was founded by K. Christopher Garcia, Roeland Nusse, Calvin J. Kuo, Hans Claudia and Claudia Janda in 2015 and is headquartered in South San Francisco, CA. | 3 years |
| Timothy Kutzkey | M | 49 | 8 years | |
| David Goeddel | M | 72 |
Surrozen Operating, Inc.
Surrozen Operating, Inc. BiotechnologyHealth Technology Surrozen Operating, Inc. operates as a biopharmaceutical company that focuses on harnessing the Wnt pathway for applications in regenerative medicine. The firm implements a surrogate Wnt platform with the potential to unlock stem cell control in an array of human tissues. The company was founded by K. Christopher Garcia, Roeland Nusse, Calvin J. Kuo, Hans Claudia and Claudia Janda in 2015 and is headquartered in South San Francisco, CA. | 5 years |
| Anna Berkenblit | M | 54 |
Surrozen Operating, Inc.
Surrozen Operating, Inc. BiotechnologyHealth Technology Surrozen Operating, Inc. operates as a biopharmaceutical company that focuses on harnessing the Wnt pathway for applications in regenerative medicine. The firm implements a surrogate Wnt platform with the potential to unlock stem cell control in an array of human tissues. The company was founded by K. Christopher Garcia, Roeland Nusse, Calvin J. Kuo, Hans Claudia and Claudia Janda in 2015 and is headquartered in South San Francisco, CA. | 6 years |
| Christopher Chai | M | 58 |
Surrozen Operating, Inc.
Surrozen Operating, Inc. BiotechnologyHealth Technology Surrozen Operating, Inc. operates as a biopharmaceutical company that focuses on harnessing the Wnt pathway for applications in regenerative medicine. The firm implements a surrogate Wnt platform with the potential to unlock stem cell control in an array of human tissues. The company was founded by K. Christopher Garcia, Roeland Nusse, Calvin J. Kuo, Hans Claudia and Claudia Janda in 2015 and is headquartered in South San Francisco, CA. | 3 years |
| Mary Haak-Frendscho | M | 67 |
Surrozen Operating, Inc.
Surrozen Operating, Inc. BiotechnologyHealth Technology Surrozen Operating, Inc. operates as a biopharmaceutical company that focuses on harnessing the Wnt pathway for applications in regenerative medicine. The firm implements a surrogate Wnt platform with the potential to unlock stem cell control in an array of human tissues. The company was founded by K. Christopher Garcia, Roeland Nusse, Calvin J. Kuo, Hans Claudia and Claudia Janda in 2015 and is headquartered in South San Francisco, CA. | 3 years |
| Shao Lee Lin | M | 57 |
Surrozen Operating, Inc.
Surrozen Operating, Inc. BiotechnologyHealth Technology Surrozen Operating, Inc. operates as a biopharmaceutical company that focuses on harnessing the Wnt pathway for applications in regenerative medicine. The firm implements a surrogate Wnt platform with the potential to unlock stem cell control in an array of human tissues. The company was founded by K. Christopher Garcia, Roeland Nusse, Calvin J. Kuo, Hans Claudia and Claudia Janda in 2015 and is headquartered in South San Francisco, CA. | 3 years |
| Dan Troy | M | 64 |
Human Genome Sciences, Inc.
 Human Genome Sciences, Inc. Medical SpecialtiesHealth Technology Human Genome Sciences, Inc. is a biopharmaceutical company that exists to place new therapies into the hands of those battling serious disease. Its lead products include BENLYSTA for systemic lupus erythematosus and raxibacumab for inhalation anthrax. The firm's other products include, mapatumumab, darapladib, albiglutide, ZALBIN, HGS1036 and HGS1029. The company was founded by Alan G. Walton and William A. Haseltine in 1992 and is headquartered in Gaithersburg, MD. | 12 years |
| Michael Johnson | M | 68 |
University of Michigan
| - |
| Chester Koczynski | M | - |
Human Genome Sciences, Inc.
Human Genome Sciences, Inc. Medical SpecialtiesHealth Technology Human Genome Sciences, Inc. is a biopharmaceutical company that exists to place new therapies into the hands of those battling serious disease. Its lead products include BENLYSTA for systemic lupus erythematosus and raxibacumab for inhalation anthrax. The firm's other products include, mapatumumab, darapladib, albiglutide, ZALBIN, HGS1036 and HGS1029. The company was founded by Alan G. Walton and William A. Haseltine in 1992 and is headquartered in Gaithersburg, MD. | 12 years |
| Robert P. Kelch | M | - |
University of Michigan
| - |
| Wen Chen Yeh | M | 61 |
Surrozen Operating, Inc.
Surrozen Operating, Inc. BiotechnologyHealth Technology Surrozen Operating, Inc. operates as a biopharmaceutical company that focuses on harnessing the Wnt pathway for applications in regenerative medicine. The firm implements a surrogate Wnt platform with the potential to unlock stem cell control in an array of human tissues. The company was founded by K. Christopher Garcia, Roeland Nusse, Calvin J. Kuo, Hans Claudia and Claudia Janda in 2015 and is headquartered in South San Francisco, CA. | 8 years |
| Aaron Hodari | M | 37 |
University of Michigan
| 5 years |
| Geertrui Vanhove | M | 59 |
Surrozen Operating, Inc.
Surrozen Operating, Inc. BiotechnologyHealth Technology Surrozen Operating, Inc. operates as a biopharmaceutical company that focuses on harnessing the Wnt pathway for applications in regenerative medicine. The firm implements a surrogate Wnt platform with the potential to unlock stem cell control in an array of human tissues. The company was founded by K. Christopher Garcia, Roeland Nusse, Calvin J. Kuo, Hans Claudia and Claudia Janda in 2015 and is headquartered in South San Francisco, CA. | 5 years |
| Charles Williams | M | 46 | 4 years | |
| Stephen R. Forrest | M | 73 |
University of Michigan
| 18 years |
| Anne C. Petersen | M | - |
University of Michigan
| 14 years |
| Mark S. Schlissel | M | - |
University of Michigan
| 10 years |
| Marschall Runge | M | 69 |
University of Michigan
| 9 years |
| Richard Joseph Auchus | M | - |
University of Michigan
| - |
| Justin B. Dimick | M | - |
University of Michigan
| - |
| Steven W. Pipe | M | - |
University of Michigan
| 31 years |
| Stephen Kieran | M | - |
University of Michigan
| - |
| Catherine Forbes | F | - |
University of Michigan
| - |
| William J. Williams | M | - |
University of Michigan
| - |
| Daniel Feder | M | - |
University of Michigan
| 7 years |
| Edward P. Ficaro | M | - |
University of Michigan
| - |
| Donald C. Winter | M | 75 |
University of Michigan
| - |
| Rashid L. Bashshur | M | - |
University of Michigan
| - |
| Richard Williams | M | 82 |
University of Michigan
| - |
| Barry Blattman | M | 61 |
University of Michigan
| - |
| Ronald M. Cresswell | M | 89 |
University of Michigan
| - |
| John E. Osborn | M | 66 |
University of Michigan
| - |
| Mary L. Campbell | F | - |
University of Michigan
| - |
| W. Morris | M | 64 |
University of Michigan
| 17 years |
| Mike Beauregard | M | - |
University of Michigan
| 19 years |
| Andrea Fischer Newman | F | 65 |
University of Michigan
| 29 years |
| B. N. Bahadur | M | - |
University of Michigan
| - |
| James R. Baker | M | - |
University of Michigan
| - |
| Satish Tadikonda | M | - |
University of Michigan
| 4 years |
| Yang Dajun | M | - |
University of Michigan
| - |
| Mark C. Tomlinson | M | - |
University of Michigan
| - |
| David C. Olson | M | - |
University of Michigan
| - |
| Dana M. Muir | F | - |
University of Michigan
| - |
| Gregory Simon | M | 72 |
University of Michigan
| - |
| Sarah E. Endline | F | - |
University of Michigan
| - |
| Charles Newman | M | - |
University of Michigan
| - |
| Robert D. Sloan | M | 76 |
University of Michigan
| - |
| Alan Taub | M | 66 |
University of Michigan
| 12 years |
| Brandon Soloski | M | - |
University of Michigan
| 1 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Reda Jaber | M | - |
University of Michigan
| 10 years |
| Deirdre Connelly | F | 63 |
Human Genome Sciences, Inc.
Human Genome Sciences, Inc. Medical SpecialtiesHealth Technology Human Genome Sciences, Inc. is a biopharmaceutical company that exists to place new therapies into the hands of those battling serious disease. Its lead products include BENLYSTA for systemic lupus erythematosus and raxibacumab for inhalation anthrax. The firm's other products include, mapatumumab, darapladib, albiglutide, ZALBIN, HGS1036 and HGS1029. The company was founded by Alan G. Walton and William A. Haseltine in 1992 and is headquartered in Gaithersburg, MD. | 3 years |
| Sahijdak Walter | M | - |
University of Michigan
| 32 years |
| Robin Abrams | F | 60 | 6 years | |
| H. Watkins | M | 71 |
Human Genome Sciences, Inc.
Human Genome Sciences, Inc. Medical SpecialtiesHealth Technology Human Genome Sciences, Inc. is a biopharmaceutical company that exists to place new therapies into the hands of those battling serious disease. Its lead products include BENLYSTA for systemic lupus erythematosus and raxibacumab for inhalation anthrax. The firm's other products include, mapatumumab, darapladib, albiglutide, ZALBIN, HGS1036 and HGS1029. The company was founded by Alan G. Walton and William A. Haseltine in 1992 and is headquartered in Gaithersburg, MD. | 8 years |
| Barry A. Labinger | M | 60 |
Immunex Corp.
 Immunex Corp. BiotechnologyHealth Technology Immunex Corporation is a leading biopharmaceutical company dedicated to improving lives through immune system science innovation
Human Genome Sciences, Inc.
Human Genome Sciences, Inc. Medical SpecialtiesHealth Technology Human Genome Sciences, Inc. is a biopharmaceutical company that exists to place new therapies into the hands of those battling serious disease. Its lead products include BENLYSTA for systemic lupus erythematosus and raxibacumab for inhalation anthrax. The firm's other products include, mapatumumab, darapladib, albiglutide, ZALBIN, HGS1036 and HGS1029. The company was founded by Alan G. Walton and William A. Haseltine in 1992 and is headquartered in Gaithersburg, MD. | 10 years |
| Sachin Garg | M | - |
University of Michigan
| 4 years |
| Martin Petrik | M | - |
University of Michigan
| 4 years |
| Mark Hammitt | M | 38 |
University of Michigan
| 5 years |
| Mike Duboe | M | - |
University of Michigan
| 4 years |
| Sean Doolan | M | - |
University of Michigan
| 12 years |
| Tanya Perkins | F | - |
University of Michigan
| 3 years |
| Marc Sehgal | M | - |
University of Michigan
| 5 years |
| Anthony Berardi | M | - |
University of Michigan
| 3 years |
| Navot Bar | M | 52 |
University of Michigan
| 3 years |
| Andy Fleszar | M | - |
University of Michigan
| 6 years |
| Michele Everard | F | 72 |
University of Michigan
| - |
| Nathan Pacer | M | - |
University of Michigan
| 4 years |
| Paskal Theo | M | - |
University of Michigan
| 5 years |
| Mike Flanagan | M | - |
University of Michigan
| 10 years |
| Ray Zhang | M | - |
University of Michigan
| 7 years |
| Mark LaRosa | M | - |
University of Michigan
| 6 years |
| Brian George | M | - |
University of Michigan
| 5 years |
| Maicie Jones | F | - |
University of Michigan
| 12 years |
| Aron Corin | M | - |
University of Michigan
| 6 years |
| Sayed Hassaballah | M | - |
University of Michigan
| 5 years |
| Valerie Chase | F | 41 |
University of Michigan
| 5 years |
| David M. Flannery | M | - |
University of Michigan
| 5 years |
| Deanna S. Hatmaker | F | 59 |
University of Michigan
| 2 years |
| Daniel Quigley | M | - |
University of Michigan
| 7 years |
| Andrew McColm | M | - |
University of Michigan
| 4 years |
| Ben Lewis | M | 43 |
University of Michigan
| 7 years |
| David K. Peng | M | - |
University of Michigan
| 4 years |
| Michael W. Vostrizansky | M | - |
University of Michigan
| 5 years |
| Gabriel Andres Thoumi | M | - |
University of Michigan
| 3 years |
| Danny Weiser | M | - |
University of Michigan
| 5 years |
| Daniel J. Estes | M | 43 |
University of Michigan
| 4 years |
| Adrienne Harris | F | - |
University of Michigan
| 6 years |
| Paul Brown | M | - |
University of Michigan
| 16 years |
| Dawn Parsons | F | - |
University of Michigan
| 12 years |
| Kathryn Hill | F | 36 |
University of Michigan
| 6 years |
| Michael Woolliscroft | M | - |
University of Michigan
| 7 years |
| Richard Anthony Consul | M | - |
University of Michigan
| 11 years |
| Michael Schoonover | M | - |
University of Michigan
| 7 years |
| Lai Wei | M | - |
University of Michigan
| 5 years |
| Gary Ford | M | 51 |
University of Michigan
| - |
| Lisa McLaughlin | F | - |
University of Michigan
| 14 years |
| Melissa Fitzgerald | F | - |
University of Michigan
| 4 years |
| Janani Ramaswamy | M | - |
University of Michigan
| 8 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 100 | 100.00% |
| Ireland | 0 | -.--% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Craig Parker
- Personal Network